Overview / Abstract: |
STATEMENT OF NEED Prostate cancer is the most common tumor type among men in the United States. Typically, androgen deprivation therapy is administered for progressive disease. However, castration resistance or unresponsiveness to androgen deprivation therapy or to antiandrogens frequently develops over time. The transition from castration-sensitive to castration-resistant disease has yet to be understood and represents a significant unmet need. Metastatic CRPC is the primary cause of prostate-related mortality, accounting for an estimated 26,730 deaths annually. Median overall survival remains less than 2 years. TARGET AUDIENCE Medical oncologists, urologists, oncology advanced practitioners, oncology and urology nurses, and other health care professionals involved in the treatment of patients with castration-resistant prostate cancer. LEARNING OBJECTIVES Upon completion of this activity, participants should be able to: 1. Assess predictive and prognostic markers to refine personalized care plans for patients with metastatic CRPC |
Expiration |
Dec 17, 2018 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
1.0 |
Accreditation |
ACCME; ANCC |
Presenters / Authors / Faculty |
Tanya Dorff, MDTanya Dorff, MD (Chairperson) |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent educational grant from Bayer HealthCare Pharmaceuticals Inc. and Genzyme. |
Keywords / Search Terms |
i3 Health, CRPC, castration-resistant prostate cancer, prostate cancer, oncology, urology, CME, CE, webinar, free CE, free CME, online CE, online CME, Free CE CME |